老年慢性髓性白血病患者面临分子检测不足和酪氨酸激酶抑制剂依从性欠佳的问题
该研究利用监测、流行病学和最终结果-医疗保险数据库,纳入1192例年龄≥66岁(中位年龄74岁)的新诊断慢性髓性白血病患者,随访≥13个月。结果显示仅45.3%的患者在酪氨酸激酶抑制剂治疗第一年达到最佳qPCR监测(≥3个季度检测),最佳监测与酪氨酸激酶抑制剂依从性提高60%及5年生存改善相关。
要点
- 在1192例老年慢性髓性白血病患者中,仅45.3%在治疗第一年达到最佳qPCR监测(≥3个季度检测)。
- 最佳监测者酪氨酸激酶抑制剂依从性提高60%(OR 1.60,95%CI 1.11-2.31,P=0.01)。
- 最佳监测者5年生存改善(HR 0.66,95%CI 0.49-0.90,P<0.01)。
核心结论
- 在这项大型真实世界研究中,许多老年慢性髓性白血病患者分子监测不足,且与酪氨酸激酶抑制剂依从性降低和生存较差相关。
研究设计与样本
- 利用监测、流行病学和最终结果-医疗保险数据库识别1192例年龄≥66岁(中位年龄74岁)的新诊断慢性髓性白血病患者,随访≥13个月。
主要发现
- 965例(81.0%)患者至少接受1次检测,425例(35.7%)和540例(45.3%)分别在酪氨酸激酶抑制剂治疗第一年的1、2和≥3个季度(最佳监测)接受检测。
- 多因素分析中,诊断年份较晚和诊断前流感疫苗接种(医疗可及性的代理指标)与最佳qPCR监测相关。
- 使用低收入补贴和居住于最低社会经济地位普查区与较差监测相关。
- 最佳监测患者酪氨酸激酶抑制剂依从性提高60%(OR 1.60,95%CI 1.11-2.31,P=0.01),5年生存改善(HR 0.66,95%CI 0.49-0.90,P<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitor (TKI) use is critical in the care of patients with chronic myeloid leukemia (CML). Quantitative polymerase chain reaction (qPCR) testing for BCR-ABL1 every 3 months during the first year of TKI treatment is recommended to assure achievement of milestone response goals. Real-world evidence for the patterns of qPCR monitoring and TKI adherence in the older patient population is lacking. Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified 1192 patients aged ≥66 years (median age, 74 years) with newly diagnosed CML who were followed up for ≥13 months from TKI initiation. In total, 965 patients (81.0%) had ≥1 test, with 425 (35.7%) and 540 (45.3%) of the patients tested during 1, 2, and ≥3 quarters (optimal monitoring) of the first year from TKI initiation, respectively. In multivariable analysis, diagnosis in later years and influenza vaccination before diagnosis, a proxy for health care access, were associated with optimal qPCR monitoring. Use of low-income subsidy and residing in census tracts with the lowest socioeconomic status were associated with less optimal monitoring. Patients with optimal monitoring were 60% more likely to be TKI adherent (odds ratio, 1.60; 95% CI, 1.11-2.31; P = .01) and had improved 5-year survival (hazard ratio, 0.66; 95% CI, 0.49-0.90; P < .01) than those without such monitoring. In this large, real-world study of CML management patterns, many older patients had suboptimal molecular monitoring, which was associated with decreased TKI adherence and worse survival.
引用
- Shallis RM, Wang R, Zeidan AM, et al. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Adv. 2023. PMID: 36939371. doi:10.1182/bloodadvances.2022009074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。